Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697452 | 0.91 | MTNR1A (0.48) | ALDH1A1TBXA2RNPC1 | |
| SCHEMBL4695473 | 0.84 | ALDH1A1 (0.51) | ALDH1A1TBXA2RALOX5APCNR2CNR1 | |
| SCHEMBL4697527 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TBXA2RALOX5APPOLBHTT | |
| SCHEMBL4697825 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TBXA2RTDP1NPC1MAPT | |
| SCHEMBL6047809 | 0.81 | NPC1 (0.44) | ALDH1A1TBXA2RTDP1ALOX5APCNR2 | |
| SCHEMBL13912905 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TDP1NPC1POLBHTT | |
| SCHEMBL4693730 | 0.79 | ALDH1A1 (0.51) | ALDH1A1TDP1CNR2NPC1MAPT | |
| SCHEMBL4697723 | 0.75 | ACSS2 (0.47) | TBXA2RMAPTKCNH2 | |
| SCHEMBL4696393 | 0.75 | ALDH1A1 (0.51) | ALDH1A1TBXA2RTDP1POLBHTT | |
| SCHEMBL4695917 | 0.74 | NTRK1 (0.47) | TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| EP-1646614-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
| EP-1646614-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005002520-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | ALDH1A1 2026/4885TBXA2R 769/4885TDP1 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.